文献速递肝病消化道肿瘤与早癌

恩替卡韦治疗期间低水平病毒血症与肝细胞癌风险增加相关

Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
PubMed 文献 · Hepatology · 2016-12-24

回顾性队列分析875例接受恩替卡韦单药治疗的初治慢性乙型肝炎病毒单一感染者,比较维持病毒学应答者与出现低水平病毒血症者的肝细胞癌风险。中位随访4.5年,低水平病毒血症组5年肝细胞癌发生率14.3%高于维持病毒学应答组的7.5%(P=0.015),校正后风险比为1.98。肝硬化患者中该关联更明显,无肝硬化患者中无显著差异。

要点

  • 恩替卡韦单药治疗期间出现低水平病毒血症与肝细胞癌风险升高相关(风险比1.98)。
  • 肝硬化患者中低水平病毒血症者5年肝细胞癌发生率23.4%高于维持病毒学应答者的10.3%。
  • 无肝硬化患者中低水平病毒血症与维持病毒学应答者的肝细胞癌风险无显著差异。

核心结论

  • 恩替卡韦单药治疗期间观察到的低水平病毒血症与更高的肝细胞癌风险相关,尤其在肝硬化患者中,提示强效抗病毒治疗期间的低水平病毒血症具有临床意义。

研究设计与样本

  • 回顾性队列研究,纳入875例接受恩替卡韦单药治疗的初治慢性乙型肝炎病毒单一感染者(平均年龄47.7岁,男性564例[65.5%],肝硬化443例[50.6%]),分析肝细胞癌的发生情况。

主要发现

  • 中位随访4.5年(范围1.0-8.7年)期间,85例(9.7%)诊断为肝细胞癌。
  • 低水平病毒血症组5年肝细胞癌发生率为14.3%,维持病毒学应答组为7.5%(P=0.015)。
  • 比较低水平病毒血症与维持病毒学应答的风险比为1.98(95%CI 1.28-3.06,P=0.002,校正年龄、性别、乙型肝炎e抗原、基线HBV DNA水平和肝硬化)。
  • 肝硬化患者中,低水平病毒血症组5年肝细胞癌发生率为23.4%,维持病毒学应答组为10.3%,校正风险比为2.20(95%CI 1.34-3.60,P=0.002)。
  • 无肝硬化患者中,低水平病毒血症与维持病毒学应答之间的肝细胞癌风险无显著差异。

关键数值与推荐

  • 低水平病毒血症定义为<2,000 IU/mL可检测到的HBV DNA持续或间歇性出现。
  • 维持病毒学应答定义为HBV DNA持续检测不到(<12 IU/mL)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The long-term clinical impact of low-level viremia (LLV; <2,000 IU/mL) is not well understood. As a result, it is unclear whether the development of LLV during entecavir monotherapy requires a change in therapy. A retrospective cohort of 875 treatment-naive chronic hepatitis B virus (HBV) monoinfected patients (mean age 47.7 years, male = 564 [65.5%], cirrhosis = 443 [50.6%]) who received entecavir monotherapy were analyzed for the development of hepatocellular carcinoma (HCC). The HCC risk was compared between patients who maintained virological response (MVR), defined by persistently undetectable HBV DNA (<12 IU/mL), and patients who experienced LLV, defined by either persistent or intermittent episodes of <2,000 IU/mL detectable HBV DNA. During a median 4.5 years of follow-up (range 1.0-8.7 years), HCC was diagnosed in 85 patients (9.7%). HCC developed more frequently in patients who experienced LLV than MVR (14.3% versus 7.5% at 5 years, P = 0.015). The hazard ratio comparing those with LLV to MVR was 1.98 (95% confidence interval = 1.28-3.06, P = 0.002, adjusted for age, sex, hepatitis B e antigen, baseline HBV DNA levels, and cirrhosis). Among patients with cirrhosis, those with LLV exhibited a significantly higher HCC risk than those with MVR (HCC incidence rate at 5 years 23.4% versus 10.3%, adjusted hazard ratio = 2.20, 95% confidence interval 1.34-3.60; P = 0.002). However, for patients without cirrhosis, there was no significant difference in the HCC risk between LLV and MVR. CONCLUSION: LLV observed during entecavir monotherapy was associated with a higher risk of HCC, especially for those with cirrhosis, indicating that LLV during potent antiviral therapy is consequential. (Hepatology 2017;66:335-343).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2016. PMID: 28012257. doi:10.1002/hep.28916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。